Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Brief Summary: THe primary objective is to estimate the response rate at 6 months to Gleevec® in patients with plexiform neurofibromas